Alexion: Behind the blockbuster

In Partnering & Investment by Cameron

Since 1992 Alexion Pharmaceuticals has been a big hitter in the orphan drugs industry. despite having just one approved product on the market, Alexion’s portfolio stretches across from uremic diseases, aHUS, to neurological disorders, and acute antibody-mediated rejection. and this is all on the shoulder of what is arguably the most famous rare disease treatment in the world: Soliris.

Famous for being the most expensive drug in the world, Soliris forms the foundation for alexion’s success, as well as it’s future revenue. With a 6th orphan drug designation being awarded in the last month there would seem to be no reduction in the potential this blockbuster drug has to earn Alexion billions.

Find out who is leading Alexion to the top of the rare disease industry >